Cargando…

Safety and Efficacy of Surgery for Metastatic Tumor to the Pancreas: A Single-Center Experience

Pancreatic metastases from other neoplasms are rare. The role of surgery for this clinical entity is unclear. The aim of this study was to investigate the role of resection in patients with pancreatic secondary lesions. We observed 44 patients with pancreatic metastases from other tumors. Renal cell...

Descripción completa

Detalles Bibliográficos
Autores principales: Moletta, Lucia, Friziero, Alberto, Serafini, Simone, Grillo, Valeria, Pierobon, Elisa Sefora, Capovilla, Giovanni, Valmasoni, Michele, Sperti, Cosimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918219/
https://www.ncbi.nlm.nih.gov/pubmed/36769817
http://dx.doi.org/10.3390/jcm12031171
_version_ 1784886559981436928
author Moletta, Lucia
Friziero, Alberto
Serafini, Simone
Grillo, Valeria
Pierobon, Elisa Sefora
Capovilla, Giovanni
Valmasoni, Michele
Sperti, Cosimo
author_facet Moletta, Lucia
Friziero, Alberto
Serafini, Simone
Grillo, Valeria
Pierobon, Elisa Sefora
Capovilla, Giovanni
Valmasoni, Michele
Sperti, Cosimo
author_sort Moletta, Lucia
collection PubMed
description Pancreatic metastases from other neoplasms are rare. The role of surgery for this clinical entity is unclear. The aim of this study was to investigate the role of resection in patients with pancreatic secondary lesions. We observed 44 patients with pancreatic metastases from other tumors. Renal cell carcinoma was the most common primary tumor (n = 19, 43.2%). Thirty-seven patients underwent surgery, and pancreatic resection with curative intent was feasible in 35 cases. Fifteen patients (43.2%) experienced major postoperative complications (Clavien-Dindo > 2), and postoperative mortality rate was 5.4%. The median overall survival and disease-free survival were 38 (range 0–186) and 11 (range 0–186) months, respectively. Overall survival and disease-free survival were significantly longer for pancreatic metastases from renal cell carcinoma when compared to other primary tumors. Multivariate analysis confirmed a pathological diagnosis of metastasis from RCC as an independent prognostic factor for overall survival (OR 2.48; 95% CI, 1.00–6.14; p = 0.05). In conclusion, radical resection of metastases to the pancreas is feasible and safe, and may confer a survival benefit for selected patients. There is a clear benefit of metastasectomy in terms of patient survival for metastases from renal cell carcinoma, while for those with other primary tumors, surgery seems to be mainly palliative.
format Online
Article
Text
id pubmed-9918219
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99182192023-02-11 Safety and Efficacy of Surgery for Metastatic Tumor to the Pancreas: A Single-Center Experience Moletta, Lucia Friziero, Alberto Serafini, Simone Grillo, Valeria Pierobon, Elisa Sefora Capovilla, Giovanni Valmasoni, Michele Sperti, Cosimo J Clin Med Article Pancreatic metastases from other neoplasms are rare. The role of surgery for this clinical entity is unclear. The aim of this study was to investigate the role of resection in patients with pancreatic secondary lesions. We observed 44 patients with pancreatic metastases from other tumors. Renal cell carcinoma was the most common primary tumor (n = 19, 43.2%). Thirty-seven patients underwent surgery, and pancreatic resection with curative intent was feasible in 35 cases. Fifteen patients (43.2%) experienced major postoperative complications (Clavien-Dindo > 2), and postoperative mortality rate was 5.4%. The median overall survival and disease-free survival were 38 (range 0–186) and 11 (range 0–186) months, respectively. Overall survival and disease-free survival were significantly longer for pancreatic metastases from renal cell carcinoma when compared to other primary tumors. Multivariate analysis confirmed a pathological diagnosis of metastasis from RCC as an independent prognostic factor for overall survival (OR 2.48; 95% CI, 1.00–6.14; p = 0.05). In conclusion, radical resection of metastases to the pancreas is feasible and safe, and may confer a survival benefit for selected patients. There is a clear benefit of metastasectomy in terms of patient survival for metastases from renal cell carcinoma, while for those with other primary tumors, surgery seems to be mainly palliative. MDPI 2023-02-01 /pmc/articles/PMC9918219/ /pubmed/36769817 http://dx.doi.org/10.3390/jcm12031171 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Moletta, Lucia
Friziero, Alberto
Serafini, Simone
Grillo, Valeria
Pierobon, Elisa Sefora
Capovilla, Giovanni
Valmasoni, Michele
Sperti, Cosimo
Safety and Efficacy of Surgery for Metastatic Tumor to the Pancreas: A Single-Center Experience
title Safety and Efficacy of Surgery for Metastatic Tumor to the Pancreas: A Single-Center Experience
title_full Safety and Efficacy of Surgery for Metastatic Tumor to the Pancreas: A Single-Center Experience
title_fullStr Safety and Efficacy of Surgery for Metastatic Tumor to the Pancreas: A Single-Center Experience
title_full_unstemmed Safety and Efficacy of Surgery for Metastatic Tumor to the Pancreas: A Single-Center Experience
title_short Safety and Efficacy of Surgery for Metastatic Tumor to the Pancreas: A Single-Center Experience
title_sort safety and efficacy of surgery for metastatic tumor to the pancreas: a single-center experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918219/
https://www.ncbi.nlm.nih.gov/pubmed/36769817
http://dx.doi.org/10.3390/jcm12031171
work_keys_str_mv AT molettalucia safetyandefficacyofsurgeryformetastatictumortothepancreasasinglecenterexperience
AT frizieroalberto safetyandefficacyofsurgeryformetastatictumortothepancreasasinglecenterexperience
AT serafinisimone safetyandefficacyofsurgeryformetastatictumortothepancreasasinglecenterexperience
AT grillovaleria safetyandefficacyofsurgeryformetastatictumortothepancreasasinglecenterexperience
AT pierobonelisasefora safetyandefficacyofsurgeryformetastatictumortothepancreasasinglecenterexperience
AT capovillagiovanni safetyandefficacyofsurgeryformetastatictumortothepancreasasinglecenterexperience
AT valmasonimichele safetyandefficacyofsurgeryformetastatictumortothepancreasasinglecenterexperience
AT sperticosimo safetyandefficacyofsurgeryformetastatictumortothepancreasasinglecenterexperience